טוען...

PRSS contributes to cetuximab resistance in colorectal cancer

Cetuximab improves the survival of patients with metastatic colorectal cancer. The main limitation is primary and secondary resistance, the underlying mechanism of which requires extensive investigation. We proved that PRSS expression levels are significantly negatively associated with the sensitivi...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Sci Adv
Main Authors: Tan, Zhaoli, Gao, Lihua, Wang, Yan, Yin, Huihui, Xi, Yongyi, Wu, Xiaojie, Shao, Yong, Qiu, Weiyi, Du, Peng, Shen, Wenlong, Fu, Ling, Jia, Ru, Zhao, Chuanhua, Zhang, Yun, Zhao, Zhihu, Sun, Zhiwei, Chen, Hongxing, Hu, Xianwen, Xu, Jianming, Wang, Youliang
פורמט: Artigo
שפה:Inglês
יצא לאור: American Association for the Advancement of Science 2020
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6938705/
https://ncbi.nlm.nih.gov/pubmed/31911942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aax5576
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!